About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Death rate in Malawi falls by up to 35% due to free HIV treatment
• HIV, but not HHV-8, found to increase risk of pulmonary arterial hypertension
• Circumcision and partner reduction should be priorities for HIV prevention, say US researchers
• Does tenofovir increase the risk of efavirenz-associated liver side-effects?
• Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows
• HIV reduces body's ability to control hepatitis C replication
• BHIVA: Many patients and clinicians still need educating about the benefits of treatment
• Insulin resistance may predict risk of cardiovascular disease in HIV
• Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children
• African-Americans with HIV have higher risk of aggressive kidney disease